3SBio a Top Chinese Biotech

3SBio Inc. (SSRX - Snapshot Report) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product, EPIAO, is the number 1 brand in the erythropoietin (EPO) market.

Second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deals with US-based AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) will boost its expansion into the IV Iron market, which will sustain long-term growth.

We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a 6 to 12 month target price of $10.

Read the full analyst report on SSRX

Read the full analyst report on AMAG